3rd Annual Dementia Congress 2023
                                                           May 22-23, 2023 Vienna, Austria

                                  
             The 3rd Annual Dementia Congress 2023 will be held on May 22-23, 2023 in Vienna, Austria.

Dementia

Dementia refers to a loss of thinking, memory, and other mental abilities. Many conditions can cause dementia. A neurodegenerative disorder refers to damage or disease in the parts of your brain responsible for learning, memory, decision-making, and language. As one of the major neurocognitive disorders, dementia is not a disease. Alzheimer's disease is the most common cause of dementia and is almost always associated with 50 other conditions. There are two types of dementia: Cortical Dementia (problems with the cerebral cortex) and Subcortical Dementia (problems with the brain beneath the cortex).

Aging and Dementia

A decline in memory and other mental abilities is known as dementia. Up to 7 percent of adults 60 and older suffer from dementia, according to the Alzheimer's Association. Dementia can cause other symptoms besides memory, language, and decision-making problems. There are a variety of mood changes, including irritability and depression.

Alzheimer's disease

As a result of Alzheimer's disease, the brain shrinks (atrophies) and brain cells die, a progressive neurologic disorder. When a person's ability to function independently is affected, Alzheimer's disease is the most common cause of dementia.

Bioinformatics Approach for Dementia

Massive amounts of data can be collected with the spread of microarrays and next-generation sequencing technologies. To extract the relevant information from these collections of data, data-mining techniques for "big data" are required. Through bioinformatics studies, these techniques are applied to biological data. Bioinformatics approaches applied to omics data have revealed the complex pathology of Alzheimer's disease (AD).

Neuropharmacology

Neuropharmacology is the learning of how drugs affect cellular function in the nervous system and the neural mechanisms through which they influence behavior. Behavioral neuropharmacology and molecular neuropharmacology are the two major branches of neuropharmacology. Drug dependence and addiction are studied in behavioral neuropharmacology.

Parkinson disease

Movement is affected by Parkinson's disease, a nervous system disorder that progresses with time. A slight tremor in one hand can be the first sign of the disease. In addition to causing tremors, this disorder can also cause stiffness or sluggishness of movement. Dopamine levels drop due to nerve cell damage in the brain, causing Parkinson's symptoms.

Past Affiliates

TY Chang (Professor Geisel School of Medicine USA): TY Chang shares the same laboratory with his wife and long-term collaborator Dr. Catherine Chang at Geisel School of Medicine at Dartmouth. They have been working on cholesterol metabolism research for more than four decades. The Changs and their colleagues did groundbreaking work by identifying the gene that encodes the cholesterol storage enzyme acyl-CoA: cholesterol acyltransferase 1 (ACAT1/SOAT1). For this work, Dr. T.Y. Chang received a MERIT award from NIH, USA. More recently, the Chang lab at Dartmouth demonstrated ACAT1 as a potential target for treating several human diseases, including Alzheimer’s disease and Niemann-Pick type C disease.

Ingolf Schimke (Professor Berlin Cures GmbH Germany): Ingolf Schimke completed his Ph.D. at the age of 27 years from “Academia der Wissenschaften” of the German Democratic Republic and postdoctoral studies at “Humbold Universität zu Berlin” Medicine. Until 2014, he was a Professor of Clinical Chemistry and Laboratory Medicine at the “Charité – Universitätsmedizin Berlin” and is presently Director of Research & Development at “Berlin Cures GmbH”. He has published more than 100 papers in reputed journals. He is serving as an editorial board member of reputed journals.

Kenichi Meguro (Professor, Division of Geriatric Behavioral Neurology Tohoku University CYRIC Japan): Dr. Meguro was educated at Tohuku University at both undergraduate and postgraduate levels. He obtained his Ph.D. in Neurology and Geriatric Medicine. He has vast work experience at the Centre-CYCERON-INSERM, in France and the ADRC, Washington University in St. Louis, School of Medicine. From 2005 to the present, he is a Professor at the Department of Geriatric Behavioral Neurology, Tohoku University Graduate School of Medicine. He is board-certified by the Japanese Academic Societies in the specialty of Internal Medicine, Clinical Neurology, Stroke Medicine, Geriatric Psychiatry, and Dementia Medicine. He sat on the Editorial Board of prestigious journals such as the Alzheimer's Disease Associated Disorders, Dementia & Neuropsychology, and the International Journal of Alzheimer’s Disease

Market Analysis

Market Analysis and Insights of Dementia - Alzheimer's Disease Market

The Dementia - Alzheimer's disease market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 10% in the above-mentioned forecast period.

Dementia is a common term for a decline in mental ability harsh enough to obstruct daily life. Alzheimer's is the most common cause of dementia. Dementia defines various numbers of symptoms which includes memory loss and problems with thinking, problem-solving, or language.

The rise in prevalence of Alzheimer’s across the globe is among the important factor expected to intensify the growth and demand of the dementia - Alzheimer disease market. In addition, the rise in the geriatric population and increase in awareness regarding neurodegenerative diseases in developing countries are also expected to contribute to the growth in the global market over the forecast period of 2021 to 2028. Also, the strong pipeline of innovative treatment options and huge healthcare spending is also likely to enhance the growth of the market. Furthermore, the high demand for personalized drugs and affordable diagnostics tests are also one of the significant factors expected to fuel the development of the dementia - Alzheimer's disease market.  

The increase in research and development activities in disease-modifying drugs and rapid surge in investment by major key players in the clinical studies of advanced treatment options are anticipated to offer significant growth opportunities for the market in the forecast period of 2021 to 2028.

Registration Link: https://dementia.global-summit.com/registration.php

Georgina Henderson
Program Manager | Dementia 2023
Mail: dementiacongress@eurosessions.com
WhatsApp: +44-7915638336